2020 Q4 Form 10-Q Financial Statement

#000117184320008002 Filed on November 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $81.00K $0.00 $0.00
YoY Change
Cost Of Revenue $36.00K
YoY Change
Gross Profit $45.00K
YoY Change
Gross Profit Margin 55.56%
Selling, General & Admin $1.331M $1.458M $2.301M
YoY Change -40.42% -36.64% 75.65%
% of Gross Profit 2957.78%
Research & Development $678.0K $1.286M $3.954M
YoY Change -82.67% -67.48% -56.68%
% of Gross Profit 1506.67%
Depreciation & Amortization $0.00 $56.00K $72.00K
YoY Change -100.0% -22.22% -89.61%
% of Gross Profit 0.0%
Operating Expenses $2.009M $2.744M $6.255M
YoY Change -67.31% -56.13% -40.07%
Operating Profit -$1.964M -$8.034M -$6.255M
YoY Change -68.04% 28.44%
Interest Expense -$1.256M $2.030M -$14.86M
YoY Change -79.0% -113.66% 20.95%
% of Operating Profit
Other Income/Expense, Net -$1.256M $1.888M -$14.90M
YoY Change -78.99% -112.67% 745050.0%
Pretax Income -$3.220M -$6.146M -$21.16M
YoY Change -73.43% -70.95% -6.91%
Income Tax
% Of Pretax Income
Net Earnings -$3.220M -$6.146M -$21.16M
YoY Change -73.44% -70.95% -6.91%
Net Earnings / Revenue -3975.31%
Basic Earnings Per Share
Diluted Earnings Per Share -$233.2K -$516.9K -$254.6K
COMMON SHARES
Basic Shares Outstanding 96.89M 96.89M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.92M $11.55M $20.23M
YoY Change 36.96% -42.9% 238.92%
Cash & Equivalents $26.55M $11.55M $19.50M
Short-Term Investments $1.372M $20.36K
Other Short-Term Assets $1.647M $1.536M $515.2K
YoY Change -11.62% 198.14% 134.18%
Inventory $14.00K
Prepaid Expenses $559.0K $489.0K
Receivables $619.0K $625.0K $995.9K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $30.20M $13.71M $21.74M
YoY Change 28.6% -36.93% 195.36%
LONG-TERM ASSETS
Property, Plant & Equipment $105.0K $119.0K $2.297M
YoY Change -95.34% -94.82% -24.36%
Goodwill
YoY Change
Intangibles $0.00 $0.00
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $436.1K
YoY Change -26.33%
Total Long-Term Assets $105.0K $119.0K $7.886M
YoY Change -98.57% -98.49% -37.21%
TOTAL ASSETS
Total Short-Term Assets $30.20M $13.71M $21.74M
Total Long-Term Assets $105.0K $119.0K $7.886M
Total Assets $30.30M $13.83M $29.63M
YoY Change -1.72% -53.31% 48.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.100M $3.670M $10.53M
YoY Change -78.55% -65.16% -20.04%
Accrued Expenses $105.0K $81.00K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $1.503M
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.248M $3.751M $12.04M
YoY Change -80.18% -68.84% -8.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $2.340M $1.208M $18.90M
YoY Change -90.41% -93.61% -4.82%
Total Long-Term Liabilities $2.340M $1.208M $18.90M
YoY Change -90.41% -93.61% -12.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.248M $3.751M $12.04M
Total Long-Term Liabilities $2.340M $1.208M $18.90M
Total Liabilities $4.588M $4.959M $30.93M
YoY Change -87.16% -83.97% -10.96%
SHAREHOLDERS EQUITY
Retained Earnings -$140.4M -$137.2M
YoY Change
Common Stock $162.2M $142.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.72M $8.873M -$759.0K
YoY Change
Total Liabilities & Shareholders Equity $30.30M $13.83M $29.63M
YoY Change -1.72% -53.31% 48.73%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$3.220M -$6.146M -$21.16M
YoY Change -73.44% -70.95% -6.91%
Depreciation, Depletion And Amortization $0.00 $56.00K $72.00K
YoY Change -100.0% -22.22% -89.61%
Cash From Operating Activities -$4.214M -$4.178M -$6.152M
YoY Change -40.68% -32.09% -6.08%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$33.00K -$17.00K
YoY Change -100.0% 94.12% -93.31%
Acquisitions
YoY Change
Other Investing Activities -$1.372M $0.00 $3.383M
YoY Change 1375.27% -100.0% 5538.33%
Cash From Investing Activities -$1.372M -$33.00K $3.366M
YoY Change 295.39% -100.98% -1835.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $19.75M $3.435M $0.00
YoY Change 228.97% -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.75M $3.434M 6.596M
YoY Change 177.43% -47.94% -5213.18%
NET CHANGE
Cash From Operating Activities -4.214M -$4.178M -6.152M
Cash From Investing Activities -1.372M -$33.00K 3.366M
Cash From Financing Activities 19.75M $3.434M 6.596M
Net Change In Cash 14.99M -$570.0K 3.519M
YoY Change 5432.84% -116.2% -151.2%
FREE CASH FLOW
Cash From Operating Activities -$4.214M -$4.178M -$6.152M
Capital Expenditures $0.00 -$33.00K -$17.00K
Free Cash Flow -$4.214M -$4.145M -$6.135M
YoY Change -38.48% -32.44% -2.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
30000000
CY2020Q2 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
75000000
CY2019Q1 acst Atthemarket Sales Agreement Term
AtthemarketSalesAgreementTerm
P3Y
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Type
DocumentType
10-Q
CY2020Q2 acst Atthemarket Sales Agreement Underwriter Fees Percentage Of Sales
AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales
0.03
CY2020Q3 acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
-31000
CY2019Q3 acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
-101000
acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
-151000
acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
224000
CY2020Q3 acst Fair Value Of Derivative Warrants Liability Reclassified To Equity
FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity
CY2019Q3 acst Fair Value Of Derivative Warrants Liability Reclassified To Equity
FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity
9890000
acst Fair Value Of Derivative Warrants Liability Reclassified To Equity
FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity
acst Fair Value Of Derivative Warrants Liability Reclassified To Equity
FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity
9904000
CY2020Q3 acst Increase Decrease In Unpaid Fixed Assets
IncreaseDecreaseInUnpaidFixedAssets
CY2019Q3 acst Increase Decrease In Unpaid Fixed Assets
IncreaseDecreaseInUnpaidFixedAssets
17000
acst Increase Decrease In Unpaid Fixed Assets
IncreaseDecreaseInUnpaidFixedAssets
acst Increase Decrease In Unpaid Fixed Assets
IncreaseDecreaseInUnpaidFixedAssets
CY2020Q3 acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
2217000
CY2019Q3 acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
1244000
acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
3395000
acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
868000
CY2020Q3 acst Interest Payable Included In Payables
InterestPayableIncludedInPayables
CY2019Q3 acst Interest Payable Included In Payables
InterestPayableIncludedInPayables
30000
acst Interest Payable Included In Payables
InterestPayableIncludedInPayables
acst Interest Payable Included In Payables
InterestPayableIncludedInPayables
30000
acst Proceeds From Nrcirap
ProceedsFromNRCIRAP
79000
CY2020Q3 acst Stock Issued As Settlement
StockIssuedAsSettlement
CY2019Q3 acst Stock Issued As Settlement
StockIssuedAsSettlement
acst Stock Issued As Settlement
StockIssuedAsSettlement
acst Stock Issued As Settlement
StockIssuedAsSettlement
680000
CY2019Q2 acst Stock Issued During Period Value Settlements
StockIssuedDuringPeriodValueSettlements
739000
CY2019Q2 acst Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
34000
CY2019Q3 acst Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
16518000
CY2020Q2 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
122000
CY2020Q3 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
142000
CY2019Q3 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
264000
acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
dei Entity Central Index Key
EntityCentralIndexKey
0001444192
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
96892537
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Registrant Name
EntityRegistrantName
Acasti Pharma Inc.
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Security12b Title
Security12bTitle
Common Shares, no par value per share
dei Trading Symbol
TradingSymbol
acst
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3670000
CY2020Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7319000
CY2020Q3 us-gaap Accretion Expense
AccretionExpense
CY2019Q3 us-gaap Accretion Expense
AccretionExpense
40000
us-gaap Accretion Expense
AccretionExpense
us-gaap Accretion Expense
AccretionExpense
77000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7400000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7887000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10855000
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9797000
CY2020Q3 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-1985000
CY2019Q3 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-4908000
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-4974000
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-12074000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
18000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
319000
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
482000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
781000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
963000
CY2020Q3 us-gaap Assets
Assets
13832000
CY2020Q1 us-gaap Assets
Assets
22853000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
13713000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
18462000
CY2020Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
1047000
CY2020Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
2578000
CY2020Q3 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
CY2019Q3 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
219000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
219000
CY2020Q3 us-gaap Cash
Cash
6064000
CY2019Q3 us-gaap Cash
Cash
2615000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11552000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14240000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12122000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15977000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14240000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16871000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11552000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19496000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-570000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3519000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2688000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2625000
CY2020Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
5488000
CY2019Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16881000
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2206031
CY2020Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2206031
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
142570000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
137424000
CY2020Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
CY2020Q1 us-gaap Deferred Costs Current
DeferredCostsCurrent
121000
CY2020Q3 us-gaap Depreciation
Depreciation
56000
CY2019Q3 us-gaap Depreciation
Depreciation
72000
us-gaap Depreciation
Depreciation
142000
us-gaap Depreciation
Depreciation
161000
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1170000
CY2020Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2393000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2020Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
238000
CY2019Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-190000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
810000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-137000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2027000
CY2019Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
14942000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1518000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
15874000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-12000
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-16000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
50000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
40000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
20000
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-64000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
154000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
45000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1324000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1555000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2973000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2671000
CY2020Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3706000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3706000
CY2019Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1584000
CY2019Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1584000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
CY2020Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1584000
CY2019Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1584000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
CY2020Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2348000
CY2019Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1839000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3892000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1651000
CY2020Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-24000
CY2019Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-24000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
CY2020Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-250000
CY2019Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-185000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-544000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-556000
CY2020Q3 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
119000
CY2019Q3 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-427000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
47000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-227000
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
CY2020Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4244000
CY2020Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
CY2019Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
30000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
60000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
15000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
125000
us-gaap Investment Income Interest
InvestmentIncomeInterest
39000
us-gaap Investment Income Interest
InvestmentIncomeInterest
228000
CY2020Q3 us-gaap Liabilities
Liabilities
4959000
CY2020Q1 us-gaap Liabilities
Liabilities
9859000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13832000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22853000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3751000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7395000
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"></td> <td style="width: 0.25in"><div style="display: inline; font-style: italic; font: inherit;">1.</div></td> <td style="text-align: justify; padding-right: 5.65pt">Nature of Operation:</td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in">&nbsp;</div> <div style=" margin: 0pt 5.9pt 0pt 0.5in; font-size: 10pt; text-align: justify">Acasti Pharma Inc. (&#x201c;Acasti&#x201d; or the &#x201c;Corporation&#x201d;) is incorporated under the Business Corporations Act (Qu&eacute;bec) (formerly Part <div style="display: inline; font-style: italic; font: inherit;">1A</div> of the Companies Act (Qu&eacute;bec)). The Corporation is domiciled in Canada and its registered office is located at <div style="display: inline; font-style: italic; font: inherit;">3009,</div> boul.de la Concord Est, Laval, Qu&eacute;bec, <div style="display: inline; font-style: italic; font: inherit;">H7E</div> <div style="display: inline; font-style: italic; font: inherit;">2B5.</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in">In <div style="display: inline; font-style: italic; font: inherit;"> August 2020, </div>the Corporation released Phase <div style="display: inline; font-style: italic; font: inherit;">3</div> clinical study results for the Corporation's lead drug candidate, CaPre. The failure of the studies to meet the primary endpoint resulted in the Corporation making a decision <div style="display: inline; font-style: italic; font: inherit;">not</div> to proceed with a filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in">In <div style="display: inline; font-style: italic; font: inherit;"> September 2020, </div>the Corporation has commenced a formal process to explore and evaluate strategic alternatives to enhance shareholder value. Towards this end, the Corporation has engaged a financial advisor to assist in the process. There can be <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance of a successful outcome from these efforts, or of the form or timing of any such outcome. The Corporation has greatly reduced its research and development activities including a reduction in workforce to reduce operating expenses, while it evaluates these opportunities. The Corporation's operations are now primarily focused on evaluating these opportunities. The Corporation remains subject to a number of risks similar to other companies in the biotechnology industry, including compliance with government regulations, protection of proprietary technology, dependence on <div style="display: inline; font-style: italic; font: inherit;">third</div> parties and product liability.</div></div>
CY2020Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3434000
CY2019Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6596000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5067000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6596000
CY2020Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33000
CY2019Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3366000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-69000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8884000
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4178000
CY2019Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6152000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8345000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12942000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4666000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6146000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-8846000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-21158000
us-gaap Net Income Loss
NetIncomeLoss
-10812000
us-gaap Net Income Loss
NetIncomeLoss
-30004000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1888000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14903000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1343000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15743000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8034000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6255000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12155000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14261000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
81000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
76000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
71000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
119000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
147000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
308000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
179000
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
51000
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-64000
CY2020Q3 us-gaap Paid In Kind Interest
PaidInKindInterest
CY2019Q3 us-gaap Paid In Kind Interest
PaidInKindInterest
40000
us-gaap Paid In Kind Interest
PaidInKindInterest
us-gaap Paid In Kind Interest
PaidInKindInterest
77000
CY2020Q3 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
33000
CY2019Q3 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
17000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
69000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
36000
CY2020Q3 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1000
CY2019Q3 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
36000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
143000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
36000
CY2020Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
21000
CY2019Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
11000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
21000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
2030000
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
489000
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
977000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3435000
CY2019Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5210000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2020Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
21000
CY2019Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
3394000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
21000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
10950000
CY2020Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2019Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
CY2020Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2019Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6619000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6619000
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
625000
CY2020Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
546000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1286000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3954000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3042000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10144000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137152000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126340000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
134000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
746000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
850000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1446000
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
401000
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
650000
us-gaap Share Based Compensation
ShareBasedCompensation
1033000
us-gaap Share Based Compensation
ShareBasedCompensation
900000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1765000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3427000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
635000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
377000
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
252000
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
670000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
12994000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
11036000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
8873000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
11045000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
3275000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-759000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"><div style="display: inline; font-weight: bold;">Use of estimates</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Actual results <div style="display: inline; font-style: italic; font: inherit;"> may </div>differ from these estimates.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">Estimates are based on management's best knowledge of current events and actions that management <div style="display: inline; font-style: italic; font: inherit;"> may </div>undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">Estimates and assumptions include the measurement of derivative warrant liabilities (note <div style="display: inline; font-style: italic; font: inherit;">6</div>) and stock-based compensation (note <div style="display: inline; font-style: italic; font: inherit;">10</div>), impairment of intangibles and assets held for sale (notes <div style="display: inline; font-style: italic; font: inherit;">4</div> and <div style="display: inline; font-style: italic; font: inherit;">5</div>) and the take-or-pay contract (note <div style="display: inline; font-style: italic; font: inherit;">12</div>(a)). Estimates and assumptions are also involved in measuring the accrual of services rendered with respect to research and developments expenditures at each reporting date, as well as in determining which research and development expenses qualify for investment tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and, therefore, could be different from the amounts recorded.</div></div></div>
CY2020Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
881000
CY2020Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
881000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95119503
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83092037
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92917712
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80877225

Files In Submission

Name View Source Status
0001171843-20-008002-index-headers.html Edgar Link pending
0001171843-20-008002-index.html Edgar Link pending
0001171843-20-008002.txt Edgar Link pending
0001171843-20-008002-xbrl.zip Edgar Link pending
acst-20200930.xsd Edgar Link pending
exh_102.htm Edgar Link pending
exh_103.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
acst-20200930_cal.xml Edgar Link unprocessable
acst-20200930_def.xml Edgar Link unprocessable
acst-20200930_lab.xml Edgar Link unprocessable
acst-20200930_pre.xml Edgar Link unprocessable
acst-20200930.xml Edgar Link completed
exh_322.htm Edgar Link pending
f10q_111620p.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable